Diabetes and Mental Health

Canadian Journal of Diabetes

Volumn 37, Issue SUPPL.1, 2013, Pages

  Robinson, David J ^a   Luthra, Meera ^a   Vallis, Michael ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CLOZAPINE; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE;

ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CHOLESTEROL BLOOD LEVEL; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIABETES MELLITUS; DISTRESS SYNDROME; DRUG EFFICACY; DRUG TOLERABILITY; EATING DISORDER; FAMILY THERAPY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MENTAL DISEASE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL RATING SCALE; PSYCHOTHERAPY; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; STRESS MANAGEMENT; TREATMENT INDICATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; CANADA; DIABETES COMPLICATIONS; MENTAL HEALTH; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PSYCHOLOGY;

CANADA; DEPRESSION; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; MENTAL DISORDERS; MENTAL HEALTH; RISK FACTORS;

EID: 84876023189     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.01.026     Document Type: Article

References (113)

1. Lieberman J.A., Stroup T.S., McEvoy J.P., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
2. Brown E.S., Varghese F.P., McEwan B.S. Association of depression with medical illness: does cortisol play a role?. Biol Psychiatry 2004, 55:1-9.
3. McCreadie R.G. Diet, smoking and cardiovascular risk in people with schizophrenia. Br J Psychiatry 2003, 183:534-539. Scottish Schizophrenia Lifestyle Group.
4. Anderson R.J., Freedland K.E., Clouse R.E., et al. The prevalence of co-morbid depression in adults with diabetes. Diabetes Care 2001, 6:1069-1078.
5. Ali S., Stone M., Peters J., et al. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2006, 23:1165-1173.
6. Barnard K., Skinner T., Peveler R. The prevalence of co-morbid depression in adults with type 1 diabetes. Diabet Med 2006, 23:445-448.
7. Egede L.E. Diabetes, major depression, and functional disability among US adults. Diabetes Care 2004, 27:421-428.
8. Moussavi S., Chatterji S., Verdes E., et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007, 370:851-858.
9. Mezuk B., Eaton W.W., Albrecht S., et al. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care 2008, 31:2383-2390.
10. Egede L.E., Nietert P.J., Zheng D. Depression and all-cause and coronary mortality among adults with and without diabetes. Diabetes Care 2005, 28:1339-1345.
11. Ludman E.J., Katon W., Russo J., et al. Depression and diabetes symptom burden. Gen Hosp Psychiatry 2004, 26:430-436.
12. Peyrot M., Rubin R.R. Persistence of depressive symptoms in diabetic adults. Diabetes Care 1999, 22:448-452.
13. Engum A., Mykletun A., Midthjell K., et al. Depression and diabetes: a large population-based study of sociodemographic, lifestyle and clinical factors associated with depression in type 1 and type 2 diabetes. Diabetes Care 2005, 28:1904-1909.
14. Katon W.J., Simon G., Russo J., et al. Quality of depression care in a population-based sample of patients with diabetes and major depression. Med Care 2004, 42:1222-1229.
15. Eaton W., Shao H., Nestadt G., et al. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry 2008, 65:513-520.
16. Kendler K.S., Karkowski L.M., Prescott C.A. Causal relationship between stressful life events and the onset of major depression. Am J Psychiatry 1999, 156:837-841.
17. Carvalhais S., Lima-Costa M., Peixoto S., et al. The influence of socio-economic conditions on the prevalence of depressive symptoms and its covariates in an elderly population with slight income differences; the Bambui Health and Aging Study. Int J Soc Psychiatry 2008, 54:447-456.
18. Katon W., Russo J., Lin E.H.B., et al. Depression and diabetes: factors associated with major depression at five-year follow-up. Psychosomatics 2009, 50:570-579.
19. Bruce D.G., Davis W.A., Davis T.M.E. Longitudinal predictors of reduced mobility and physical disability in patients with type 2 diabetes. Diabetes Care 2005, 28:2441-2447.
20. Lawlor D.A., Smith G.D., Ebrahim S. Association of insulin resistance with depression: cross sectional findings from the British Women's Heart and Health Study. BMJ 2003, 327:1383-1384.
21. Timonen M., Salmenkaita I., Jokelainen J., et al. Insulin resistance and depressive symptoms in young adult males: findings from Finnish military conscripts. Psychosom Med 2007, 69:723-728.
22. Okamura F., Tashiro A., Utumi A., et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism 2000, 49:1255-1260.
23. Anagnostis P. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab 2009, 94:2692-2701.
24. Pariante C., Miller A. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001, 49:391-404.
25. Belmaker R., Agam G. Major depressive disorder. N Engl J Med 2008, 358:55-68.
26. Ciechanowski P.S., Katon W.J., Russo J.E. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. Arch Int Med 2000, 160:3278-3285.
27. Lin E.H.B., Katon W., Von Korff M., et al. Relationship of depression and diabetes self-care, medication adherence, and preventative care. Diabetes Care 2004, 27:2154-2160.
28. Katon W.J., Rutter C., Simon G. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005, 28:2668-2672.
29. Zhang X., Norris S.L., Gregg E.W. Depressive symptoms and mortality among persons with and without diabetes. Am J Epidemiol 2005, 161:652-660.
30. Lustman P.J., Clouse R.E., Freedland K.E., et al. Effects of nortriptyline on depression and glucose regulation in diabetes: results of a double-blind placebo-controlled trial. Psychosom Med 1997, 59:241-250.
31. Lustman P.J., Freedland K.E., Griffith L., et al. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000, 23:618-623.
32. Lustman P.J., Clouse R.E., Nix B.D., et al. Sertraline for prevention of depression recurrence in diabetes mellitus. Arch Gen Psychiatry 2006, 63:521-529.
33. Lustman P.J., Griffith L.S., Freedland K.E., et al. Cognitive behaviour therapy for depression in type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1998, 129:613-621.
34. Fagiolini A., Frank E., Scott J.A., et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005, 7:424-430.
35. Taylor V., MacQueen G. Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006, 67:1034-1041.
36. van Winkel R., De Hert M., Van Eyck D., et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord 2008, 10:342-348.
37. Katon W.J., Lin E.H., Kroenke K. The association of depression and anxiety with the medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007, 29:147-155.
38. Grigsby A.B., Anderson R.J., Freedland K.E., et al. Prevalence of anxiety in adults with diabetes: a systematic review. J Psychosom Res 2004, 27:1053-1060.
39. Crow S., Kendall D., Praus B., et al. Binge eating and other psychopathology in patients with type II diabetes mellitus. Int J Eat Disord 2000, 30:222-226.
40. Jones J.M., Lawson M.L., Daneman D. Eating disorders in adolescent females with and without type 1 diabetes: cross sectional study. BMJ 2000, 320:1563-1566.
41. McCarthy M. The thin ideal. depression and eating disorders in women. Behav Res Ther 1990, 28:205-214.
42. Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, American Psychiatric Association, Arlington, VA. 4th ed, text revision.
43. Iafusco D., Vanelli M., Gugliotta M., et al. Prevalence of eating disorders in young patients with type 1 diabetes from two different Italian cities. Diabetes Care 2004, 27:2278.
44. Morse S., Ciechanowski P., et al. Isn't this just bedtime snacking? The potential adverse effects of night-eating symptoms on treatment adherence and outcomes in patients with diabetes. Diabetes Care 2006, 29:1800-1804.
45. Haupt D.W., Newcomber J.W. Hyperglycemia and antipsychotic medications. J Clin Psych 2001, 62:15-26.
46. Saddichha S., Manjunatha N., Ameen S., et al. Diabetes and schizophrenia: effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 2008, 117:342-347.
47. McEvoy J.P., Meyer J.M., Goff D.C., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schiz Res 2005, 80:19-32.
48. Meyer J.M., Nasrallah H.A. Medical Illness and Schizophrenia 2009, American Psychiatric Publishing, Inc., Arlington, Virginia (VA). 2nd ed.
49. Smith R. The macrophage theory of depression. Med Hypothesis 1991, 35:298-306.
50. Fernandez-Real J.M., Pickup J.C. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2008, 19:10-16.
51. Serretti A., Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010, 71:1259-1272.
52. Spoelstra J.A., Stolk R.P., Cohen D., et al. Antipsychotic drugs may worsen metabolic control in type 2 diabetes mellitus. J Clin Psychiatry 2004, 65:674-678.
53. Newcomer J.W., Haupt D.W. The metabolic effects of antipsychotic medications. Can J Psychiatry 2006, 51:480-491.
54. Lambert T.J., Chapman L.H. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004, 181:544-548.
55. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 2004, 27:596-601.
56. De Nayer A., De Hert M., Scheen A., Van Gaal L., Peuskens J. Belgian consensus on metabolic problems associated with atypical antipsychotics. Int J Psychiatry Clin Pract 2005, 9:130-137.
57. Snoek F.J., Kersch N.Y., Eldrup E., et al. Monitoring of Individual Needs in Diabetes (MIND): baseline data from the Cross-National Diabetes Attitudes, Wishes, and Needs (DAWN) MIND study. Diabetes Care 2011, 34:601-603.
58. Peyrot M., Rubin R.R., Lauritzen T., et al. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med 2005, 22:1379-1385.
59. Goebel-Fabbri A.E., Fikkan J., Franko D.L., et al. Insulin restriction and associated morbidity and mortality in women with type 1 diabetes. Diabetes Care 2008, 31:415-419.
60. Fisher L., Glasgow R.E. A call for more effectively integrating behavioral and social science principles into comprehensive diabetes care. Diabetes Care 2007, 30:2746-2749.
61. Malik J.A., Koot H.M. Explaining the adjustment of adolescents with type 1 diabetes: role of diabetes-specific and psychosocial factors. Diabetes Care 2009, 32:774-779.
62. Zhang C.X., Tse L.A., Ye X.Q., et al. Moderating effects of coping styles on anxiety and depressive symptoms caused by psychological stress in Chinese patients with Type 2 diabetes. Diabet Med 2009, 26:1282-1288.
63. Hampson S.E., Tildesley E., Andrews J.A., et al. The relation of change in hostility and sociability during childhood to substance use in mid adolescence. J Res Pers 2010, 44:103-114.
64. Luyckx K., Seiffge-Krenke I., Hampson S.E. Glycemic control, coping, and internalizing and externalizing symptoms in adolescents with type 1 diabetes: a cross-lagged longitudinal approach. Diabetes Care 2010, 33:1424-1429.
65. Anderson R.M. Is the problem of compliance all in our heads?. Diabetes Educ 1985, 11:31-34.
66. Gonzalez J.S., Peyrot M., McCarl L.A., et al. Depression and diabetes treatment nonadherence: a meta-analysis. Diabetes Care 2008, 31:2398-2403.
67. Gonzalez J.S., Safren S.A., Delahanty L.M., et al. Symptoms of depression prospectively predict poorer self-care in patients with Type 2 diabetes. Diabet Med 2008, 25:1102-1107.
68. Egede L.E., Grubaugh A.L., Ellis C. The effect of major depression on preventive care and quality of life among adults with diabetes. Gen Hosp Psychiatry 2010, 32:563-569.
69. Richardson L.K., Egede L.E., Mueller M. Effect of race/ethnicity and persistent recognition of depression on mortality in elderly men with type 2 diabetes and depression. Diabetes Care 2008, 31:880-881.
70. Hutter N., Schnurr A., Baumeister H. Healthcare costs in patients with diabetes mellitus and comorbid mental disorders: a systematic review. Diabetologia 2010, 53:2470-2479.
71. Li C., Ford E.S., Zhao G., et al. Prevalence and correlates of undiagnosed depression among U.S. adults with diabetes: the Behavioral Risk Factor Surveillance System, 2006. Diabetes Res Clin Pract 2009, 83:268-279.
72. Fisher L., Skaff M.M., Mullan J.T., et al. Clinical depression versus distress among patients with type 2 diabetes: not just a question of semantics. Diabetes Care 2007, 30:542-548.
73. Gonzalez J.S., Fisher L., Polonsky W.H. Depression in diabetes: have we been missing something important?. Diabetes Care 2011, 34:236-239.
74. Fisher L., Glasgow R.E., Strycker L.A. The relationship between diabetes distress and clinical depression with glycemic control among patients with type 2 diabetes. Diabetes Care 2010, 33:1034-1036.
75. Fisher L., Mullan J.T., Arean P., et al. Diabetes distress but not clinical depression or depressive symptoms is associated with glycemic control in both cross-sectional and longitudinal analyses. Diabetes Care 2010, 33:23-28.
76. Pignone M.P., Gaynes B.N., Rushton J.L., et al. Screening for depression in adults, a summary of the evidence for the US Preventative Services Task Force. Ann Intern Med 2002, 136:765-776.
77. Polonsky W.H., Anderson B.J., Lohrer P.A., et al. Assessment of diabetes-related distress. Diabetes Care 1995, 18:754-760.
78. van Bastelaar K.M., Pouwer F., Geelhoed-Duijvestijn P.H., et al. Diabetes-specific emotional distress mediates the association between depressive symptoms and glycaemic control in Type 1 and Type 2 diabetes. Diabet Med 2010, 27:798-803.
79. Polonsky W.H., Fisher L., Earles J., et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care 2005, 28:626-631.
80. Furuya M., Hayashino Y., Tsujii S., et al. Comparative validity of the WHO-5 Well-Being Index and two-question instrument for screening depressive symptoms in patients with type 2 diabetes. Acta Diabetol 2010 Aug 27, [Epub ahead of print].
81. Collins M.M., Corcoran P., Perry I.J. Anxiety and depression symptoms in patients with diabetes. Diabet Med 2009, 26:153-161.
82. Kroenke K., Spitzer R.L. The PHQ-9: a new depression diagnostic and severity measure. Psychiatr Ann 2002, 32:509-521.
83. van Steenbergen-Weijenburg K.M., de Vroege L., Ploeger R.R., et al. Validation of the PHQ-9 as a screening instrument for depression in diabetes patients in specialized outpatient clinics. BMC Health Serv Res 2010, 10:235.
84. Fisher L., Skaff M.M., Mullan J.T., et al. A longitudinal study of affective and anxiety disorders, depressive affect and diabetes distress in adults with Type 2 diabetes. Diabet Med 2008, 25:1096-1101.
85. Mantyselka P., Korniloff K., Saaristo T., et al. Association of depressive symptoms with impaired glucose regulation, screen-detected, and previously known type 2 diabetes: findings from the Finnish D2D Survey. Diabetes Care 2011, 34:71-76.
86. Piatt G.A., Anderson R.M., Brooks M.M., et al. 3-year follow-up of clinical and behavioral improvements following a multifaceted diabetes care intervention: results of a randomized controlled trial. Diabetes Educ 2010, 36:301-309.
87. Osborn C.Y., Egede L.E. Validation of an Information-Motivation-Behavioral Skills model of diabetes self-care (IMB-DSC). Patient Educ Couns 2010, 79:49-54.
88. Maindal H.T., Sandbaek A., Kirkevold M., Lauritzen T. Effect on motivation, perceived competence, and activation after participation in the "Ready to Act" programme for people with screen-detected dysglycaemia: a 1-year randomised controlled trial, Addition-DK. Scand J Public Health 2011, 39:262-271.
89. Attari A., Sartippour M., Amini M., Haghighi S. Effect of stress management training on glycemic control in patients with type 1 diabetes. Diabetes Res Clin Pract 2006, 73:23-28.
90. Soo H., Lam S. Stress management training in diabetes mellitus. J Health Psychol 2009, 14:933-943.
91. Keogh K.M., Smith S.M., White P., et al. Psychological family intervention for poorly controlled type 2 diabetes. Am J Manag Care 2011, 17:105-113.
92. Wysocki T., Harris M.A., Buckloh L.M., et al. Randomized trial of behavioral family systems therapy for diabetes: maintenance of effects on diabetes outcomes in adolescents. Diabetes Care 2007, 30:555-560.
93. Wysocki T., Harris M.A., Buckloh L.M., et al. Randomized, controlled trial of behavioral family systems therapy for diabetes: maintenance and generalization of effects on parent-adolescent communication. Behav Ther 2008, 39:33-46.
94. Katon W.J., Lin E.H.B., Von Korff M., et al. Collaborative care for patients with depression and chronic illnesses. N Engl J Med 2010, 363:2611-2620.
95. van der Feltz-Cornelis C.M., Nuyen J., Stoop C., et al. Effect of interventions for major depressive disorder and significant depressive symptoms in patients with diabetes mellitus: a systematic review and meta-analysis. Gen Hosp Psychiatry 2010, 32:380-395.
96. de Groot M., Doyle T., Kushnick M., et al. Can lifestyle interventions do more than reduce diabetes risk? Treating depression in adults with type 2 diabetes with exercise and cognitive behavioral therapy. Curr Diab Rep 2012, 12:157-166.
97. Beck J.S. Cognitive Behavior Therapy: Basics and Beyond 2011, Guilford, New York. 2nd ed.
98. Wang M.Y., Tsai P.S., Chou K.R., Chen C.M. A systematic review of the efficacy of non-pharmacological treatments for depression on glycaemic control in type 2 diabetics. J Clin Nurs 2008, 17:2524-2530.
99. Winkley K., Ismail K., Landau S., Eisler I. Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials. BMJ 2006, 333:65.
100. Xia Z., DePierre J., Nassberger L. Tricyclic antidepressants inhibit IL-6, IL-1beta, and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 1996, 34:27-37.
101. Maes M., Song C., Lin A., et al. Negative immunomodulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999, 20:370-379.
102. Kaufmann R.P., Castracane V.D., White D.L. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. Gynecol Endocrinol 2005, 21:129-137.
103. Weber-Hamann B., Giles M., Lederbogen F., et al. Improved insulin sensitivity in 80 nondiabetic patients with major depressive disorder after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry 2006, 67:1856-1861.
104. Allison D.B., Mentore J.L., Heo M., et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
105. Woo V., Harris S.B., Houlden R.L. Canadian Diabetes Association Position Paper: Antipsychotic Medications and Associated Risks of Weight Gain and Diabetes. Can J Diabetes 2005, 29:111-112.
106. Stroup T.S., Lieberman J.A., McEvoy J.P., et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006, 163:611-622.
107. Stroup T.S., McEvoy J.P., Ring K.D. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011, 168:947-956.
108. Stahl S.M. The Prescriber's Guide 2011, Cambridge University Press, New York, NY. 4th ed.
109. Virani A.S., Bezchlibnyk-Butler K.Z., Joel Jeffries J.J., et al. Clinical Handbook of Psychotropic Drugs 2011, Hogrefe Publishing, Toronto, Canada. 19th ed.
110. Pignone M., Gaynes B.N., Rushton J.L., et al. Screening for depression: systematic evidence review. Systematic Evidence Review No. 6. AHRQ Publication. No. 02-S002. Rockville, MD Agency for Healthcare Research and Quality 2002.
111. Ismail K., Winkley K., Rabe-Hesketh S. Systematic review and meta-analysis of randomized controlled trials of psychological interventions to improve glycaemic control in patients with type 2 diabetes. Lancet 2004, 363:1589-1597.
112. Grey M., Boland E.A., Davidson M., et al. Short-term effects of coping skills training as an adjunct to intensive therapy in adolescents. Diabetes Care 1998, 21:902-908.
113. Ellis D.A., Frey M.A., Naar-King S., et al. The effects of multisystemic therapy on diabetes stress among adolescent wit chronically poorly controlled type 1 diabetes: findings from a randomized controlled trial. Pediatrics 2005, 16:826-832.